Characterization of phentermine and related compounds as monoamine oxidase (mao) inhibitors

Biochemical Pharmacology

Volumn 59, Issue 12, 2000, Pages 1611-1621

  Ulus, Ismail H ^a   Maher, Timothy J ^b   Wurtman, Richard J ^c  

^a ULUDAG UNIVERSITY   (Turkey)

^b MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Amines; Anorectics; MAO A; MAO B; Phentermine; Serotonin

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE; ANTIDEPRESSANT AGENT; EPHEDRINE; ESTRADIOL BENZOATE; IPRONIAZID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; PHENTERMINE; PSEUDOEPHEDRINE;

ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; LIVER; LUNG; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EPHEDRINE; IPRONIAZID; LIVER; LUNG; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; PHENTERMINE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0034092058     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00306-3     Document Type: Article

References (36)

1. Connolly H.M., Crary J.L., McGoon M.D., Hensrud D.H., Edwards B.S., Edwards W.D., Schaff H.V. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
2. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine U.S. Department of Health and Human Services interim public health recommendations, November 1997 . MMWR Morb Mortal Wkly Rep. 46:1997;1061-1066.
3. Weissman N.J., Tighe J.F. Jr, Gottdiener J.S. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. N Engl J Med. 339:1998;725-732.
4. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
5. Wee C.C., Phillips R.S., Aurigemma G., Erbon S., Kriegel G., Riley M., Douglas P.S. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med. 129:1998;870-874.
6. Weissman N.J. Appetite suppressant valvulopathy A review of current data . Cardiovasc Rev Rep. 20:1999;146-155.
7. Spedding M., Ouvry C., Millan M., Duhault J., Dacquet C., Wurtman R. Neural control of dieting. Nature. 380:1996;488.
8. Weintraub M., Hasday J.D., Mushlin A.I., Lockwood D.H. A double-blind clinical trial in weight control Use of fenfluramine and phentermine alone and in combination . Arch Intern Med. 144:1984;1143-1148.
9. Physicians' Desk Reference, 53rd Edn. Medical Economics Co. 1999;Montvale, NJ.
10. Balcioglu A., Wurtman R.J. Effects of phentermine on striatal dopamine and serotonin release in conscious rats In vivo microdialysis study . Int J Obes. 22:1998;325-328.
11. Maher T.J., Ulus I.H., Wurtman R.J. Phentermine and other monoamine-oxidase inhibitors may increase plasma serotonin when given with fenfluramines. Lancet. 353:1999;38.
12. Donnelly C.H., Murphy D.L. Substrate- and inhibitor-related characteristics of human platelet monoamine oxidase. Biochem Pharmacol. 26:1977;853-858.
13. Maher T.J., Ulus I.H., Wurtman R.J. Does phentermine inhibit monoamine oxidase? Lancet. 353:1999;1362-1363.
14. Moller Nielsen I and Dubnick B, Pharmacology of chlorphentermine. In: Amphetamines and Related Compounds (Eds. Costa E and Garattini S), pp. 63-73. Raven Press, New York, 1970.
15. Seiler K.U., Wasserman O. MAO-inhibitory properties of anorectic drugs. J Pharm Pharmacol. 25:1973;576-578.
16. Wiersma D.A., Roth R.A. Clearance of 5-hydroxytryptamine by rat lung and liver The importance of relative perfusion and intrinsic clearance . J Pharmacol Exp Ther. 212:1980;97-102.
17. Lyles G.A., Callingham B.A. In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidase in rat cardiovascular tissues. Biochem Pharmacol. 31:1982;1417-1424.
18. Abenhaim L., Moride Y., Brenot F., Rich S., Benichou J., Kurz X., Higenbottam T., Oakley C., Wouters E., Aubier M., Simonneau G. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med. 335:1996;609-616.
19. Chakravorty S.G., Halbreich U. The influence of estrogen on monoamine oxidase activity. Psychopharmacol Bull. 33:1997;229-233.
20. Gerlach M., Riederer P., Youdim M.B.H. The molecular pharmacology of L-deprenyl. Eur J Pharmacol. 226:1992;97-108.
21. Mantle T.J., Tipton K.F., Garrett N.J. Inhibition of monoamine oxidase by amphetamine and related compounds. Biochem Pharmacol. 25:1976;2073-2077.
22. Scorza M.C., Carrau C., Silveira R., Zapata-Torres G., Cassels B.K., Reyes-Parada M. Monoamine oxidase inhibitory properties of some methoxylated and alkylthio amphetamine derivatives Structure-activity relationships . Biochem Pharmacol. 54:1997;1361-1369.
23. Yu P.H. Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent. Res Commun Chem Pathol Pharmacol. 51:1986;163-171.
24. Garattini S., Borroni E., Mennini T., Samanin R. Differences and similarities among anorectic agents. Garattini S., Samanin R. Central Mechanisms of Anorectic Drugs. 1978;127-143 Raven Press, New York.
25. Jenden D.J., Hinsvark O.N., Cho A.K. Some aspects of the comparative pharmacology of amphetamine and phentermine. Garattini S., Samanin R. Central Mechanisms of Anorectic Drugs. 1978;165-177 Raven Press, New York.
26. Celada P., Artigas F. Monoamine oxidase inhibitors increase preferentially extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in the awake rat. Naunyn Schmiedebergs Arch Pharmacol. 347:1993;583-590.
27. Barrett A.M., McSharry L. Inhibition of drug-induced anorexia in rats by methysergide. J Pharm Pharmacol. 27:1975;889-895.
28. Lawlor R.B., Trivedi M.C., Yelnosky J. A determination of the anorexigenic potential of dl-amphetamine, d-amphetamine, l-amphetamine and phentermine. Arch Int Pharmacodyn Ther. 179:1969;401-407.
29. Baumann M.H., Rothman R.B. Combined phentermine/fenfluramine administration and central serotonin neurons. Synapse. 28:1998;339-342.
30. Balcioglu A., Wurtman R.J. Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum In vivo microdialysis study in conscious animals . Brain Res. 813:1998;67-72.
31. Weintraub M., Sundaresan P.R., Madan M., Schuster B., Balder A., Lasagna L., Cox C. Long-term weight control study I (weeks 0 to 34). Clin Pharmacol Ther. 51:1992;586-594.
32. Gillis C.N., Cronau L.H., Mandel S., Hammond G.L. Indicator dilution measurement of 5-hydroxytryptamine clearance by human lung. J Appl Physiol. 46:1979;1178-1183.
33. Morita T., Mehendale H.M. Effects of chlorphentermine and phentermine on the pulmonary disposition of 5-hydroxytryptamine in the rat in vivo. Am Rev Respir Dis. 127:1983;747-750.
34. Seiler K.U., Wassermann O., Wensky H. On the role of serotonin in the pathogenesis of pulmonary hypertension induced by anorectic drugs; an experimental study in the isolated perfused rat lung, II. Fenfluramine, mazindol, mefenorex, phentermine and R 800. Clin Exp Pharmacol Physiol. 3:1976;323-330.
35. Nurse D, Woman sounding a warning on medication combination. Atlanta Journal Constitution J3-J4, Sept. 22, 1998.
36. Khan M.A., Herzog C.A., St. Peter J.V., Hartley G.G., Madlonkay R., Dick C.D., Asinger R.W., Vessey J.T. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 339:1998;713-718.